Trials / Completed
CompletedNCT01166490
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASG-5ME | 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2010-07-21
- Last updated
- 2013-08-27
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01166490. Inclusion in this directory is not an endorsement.